Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1220-1,05
KB10180,30
PKN82,5882,590,58
Msft497,67497,760,06
Nokia4,384,384-0,70
IBM294,03294,25-0,24
Mercedes-Benz Group AG48,9448,95-1,50
PFE24,5224,531,18
01.07.2025 16:19:10
Indexy online
AD Index online
select
AD Index online
 

  • 01.07.2025 16:14:35
Apellis Pharma Rg (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
17,77 2,66 0,46 422 215
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.07.2025
Popis společnosti
Obecné informace
Název společnostiApellis Pharmaceuticals Inc
TickerAPLS
Kmenové akcie:Ordinary Shares
RICAPLS.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 705
Akcie v oběhu k 30.04.2025 125 682 260
MěnaUSD
Kontaktní informace
Ulice100 Fifth Avenue
MěstoWALTHAM
PSČ02451
ZeměUnited States
Kontatní osobaNiel Carnahan
Funkce kontaktní osobyInvestor Contact
Telefon16 179 775 700
Fax19164431908
Kontatní telefon16 179 775 703

Business Summary: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Apellis Pharmaceuticals Inc revenues decreased 3% to $166.8M. Net loss increased 39% to $92.2M. Revenues reflect SYFOVRE segment decrease of 5% to $130.2M, EMPAVELI segment decrease of 23% to $19.7M. Higher net loss reflects Compensation and related personnel costs increase of 3% to $33.5M (expense), Research and Development - Balancing val increase of 2% to $53M (expense).
Odvětvová klasifikace
TRBC2012Biopharmaceuticals
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 01.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Co-Founder, DirectorCedric Francois52
Co-Founder, Chief Scientific OfficerPascal Deschatelets55
Chief Financial Officer, TreasurerTimothy Sullivan54
Chief Technical Operations OfficerNur Nicholson5617.08.202017.08.2020
Vice President, Corporate Controller, Chief Accounting OfficerJames Chopas5830.08.202130.08.2021
General Counsel, SecretaryDavid Watson52
Chief Medical OfficerCaroline Baumal5803.01.202303.01.2023
Chief Business and Strategy OfficerMark Delong48